EHA 2022 – Naval Daver
Naval Daver overviews the most promising new agents in the treatment of AML, how existing drugs can blend into new regimens and how the prognosis of patients with AML will evolve in the years to come. Finally, he talks about risk factors for ICI-related pneumonitis development and if pneumonitis increases mortality in AML patients.
Here is the full EHA 2022 report.
More posts
New options in untreated and pretreated mantle cell lymphoma
Patients of an advanced age with previously untreated mantle cell lymphoma (MCL) usually receive chemoimmunotherapy regimens such as bendamustine/rituximab (BR), R-CHOP or bortezomib/rituximab/cyclophosphamide/doxorubicin/prednisone (VR-CAP), with BR having become the most commonly used first-line strategy.
Prolonging remission in relapsed and refractory follicular lymphoma
Follicular lymphoma (FL) is a common indolent form of non-Hodgkin lymphoma that accounts for 20-25 % of all new NHL cases in Western countries. Although patients with FL generally respond well to first-line anti-CD20-based chemotherapy regimens, recurrence is common.
BTK inhibition in Waldenström’s macroglobulinemia: trial updates and real-world insights
The open-label, multicenter, randomized phase III ASPEN trial was set up to assess the efficacy and safety of the potent, selective, irreversible next-generation BTK inhibitor zanubrutinib in Waldenström’s macroglobulinemia (WM). Cohort 1 of the study included patients with MYD88-mutated disease (n = 201); here, zanubrutinib was compared to ibrutinib after 1:1 randomization.
Early-phase trials investigating novel agents in miscellaneous B-cell malignancies
The prognosis is still poor for most patients with relapsed or refractory large B-cell lymphoma (LBCL) irrespective of therapeutic advances that have recently been achieved. There is a need for convenient, efficacious, well-tolerated, and readily available treatment options.
Marginal zone lymphoma: benefits of BTK inhibition in later lines
Patients with marginal zone lymphoma (MZL) usually show an indolent course of disease, although MZL remains largely incurable, particularly in the relapsed/refractory setting. BTK inhibition offers a potent treatment option in this situation. The single-arm, multicenter, phase II MAGNOLIA study tested the next-generation BTK inhibitor zanubrutinib in patients with relapsed/refractory MZL who had received ≥ 1 CD20-based regimen, demonstrating high response rates and durable disease control.
Updates and ancillary analyses in the setting of chronic lymphocytic leukemia
In fit patients with advanced CLL of favorable genetic risk, chemoimmunotherapy (CIT) consisting of fludarabine/cyclophosphamide/rituximab (FCR) or bendamustine/rituximab (BR) still represents the treatment standard. Another potential strategy, however, is time-limited therapy consisting of obinutuzumab plus venetoclax (GV) with or without a BTK inhibitor.